Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XSpray Pharma ABOSTO:XSPRAY +0.22%28 Days Payable is 727.14 as of Jun. 2026. GuruFocus rates OSTO:XSPRAY with a GF Score™ of 28/100. Among 707 Biotechnology companies, XSpray Pharma AB ranks worse than 141442.57% on this metric.
The historical rank and industry rank for XSpray Pharma AB's Days Payable or its related term are showing as below:
OSTO:XSPRAY's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.24 * Ranked among companies with meaningful Days Payable only.
XSpray Pharma AB's Days Payable
increased
from Jun. 2025 (566.66) to Jun. 2026 (727.14).
It may suggest that XSpray Pharma ABdelayed paying its suppliers.
The historical data trend for XSpray Pharma AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:XSPRAY vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, XSpray Pharma AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XSpray Pharma AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Days Payable distribution charts can be found below:
* The bar in red indicates where XSpray Pharma AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
XSpray Pharma AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSpray Pharma AB (OSTO:XSPRAY) has a Days Payable of 727.14 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on XSpray Pharma AB and its competitors. According to the industry distribution chart, XSpray Pharma AB ranks #999999 out of 707 companies in the Biotechnology industry.
Is XSpray Pharma AB's Days Payable too high?
XSpray Pharma AB's current Days Payable is 727.14. The Biotechnology industry median Days Payable is 111.24. XSpray Pharma AB's value of 727.14 is 553.7% above this industry median. Based on the distribution chart, XSpray Pharma AB ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XSpray Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XSpray Pharma AB ranks #999999 out of 707 companies for Days Payable. This places XSpray Pharma AB in the lower half of its industry. The industry median Days Payable is 111.24. XSpray Pharma AB's value of 727.14 is 553.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XSpray Pharma AB's current Days Payable of 727.14 is 553.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on XSpray Pharma AB and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XSpray Pharma AB's current Days Payable is 727.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (OSTO:XSPRAY) has a current Days Payable of 727.14. The current Days Payable is 727.14 and 553.7% above the Biotechnology industry median of 111.24. XSpray Pharma AB's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For XSpray Pharma AB (OSTO:XSPRAY), the current Days Payable is 727.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
28GF Score
Get the complete analysis for OSTO:XSPRAY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:XSPRAY has been successfully added to your 
